Integrins are major adhesion-and signaling-receptor proteins that mediate cell migration and invasion. They also trigger a variety of signal transduction pathways and regulate cytoskeletal organization, specific gene expression, growth control, and apoptosis (programmed cell death). Oncogenes and tumor suppressors are believed to represent key steps in regulatory pathways controlled by soluble growth factors (1). Activation of oncogenes or inactivation of tumor suppressors can lead to irreversible activation of growth regulatory pathways and uncontrolled growth. However, it is also crucial for cancer cells to acquire the ability to escape normal tissue architecture, to invade, and to metastasize. Growth of cancer cells is generally independent not only of serum or growth factors but also of adhesion to the extracellular matrix, which normally regulates cell movement, growth, and tissue remodeling (2-5). It is well established that survival of many cell types requires integrin-mediated adhesion to extracellular matrix proteins, and loss of this requirement is a hallmark of neoplastic cells.
THE TUMOR SUPPRESSOR GENE PTEN
A number of genetic alterations are involved in the oncogenesis of cancers, including inactivation of the tumor suppressor genes p53, p16, and retinoblastoma (Rb), amplification of the gene encoding epidermal growth factor (EGF) receptor, and other molecular alterations (10) (11) (12) . One alteration that occurs at high frequency in a variety of human tumors is loss of heterozygosity at chromosome 10q23. This change occurs in the vast majority (>70%) of glioblastomas and in more than 60% of advanced prostate cancers (13) (14) (15) (16) . Independent research teams identified a novel tumor suppressor gene from this region called PTEN (phosphatase and tensin homologue deleted on chromosome 10) (17) or MMAC1 (mutated in multiple advanced cancers 1) (18) . This gene was also described as TEP1 (transforming growth factor [TGF]-␤-regulated and epithelial cell-enriched phosphatase) because its expression was rapidly repressed by TGF-␤ (19) .
It is interesting that the amino acid sequence of PTEN indicated that it resembles two different types of proteins. The PTEN gene encodes the catalytic signature motif of protein tyrosine phosphatases and functions as a dual-specificity phosphatase in vitro (19) (20) (21) , but it can also dephosphorylate the lipid signal transduction molecule PIP 3 (phosphatidylinositol 3,4,5-trisphosphate) (22) . The N-terminal domain of PTEN also shows extensive homology to the cytoskeletal protein tensin (17) (18) (19) , which plays a role in maintenance of cellular structure and possibly in signal transduction by binding to actin filaments at focal adhesions and to phosphotyrosine-containing proteins through its actin-binding and Src homology-2 (SH2) domains (23) . The PTEN gene is ubiquitously expressed in human tissues (Tamura M: unpublished data), and it is essential for embryonic development in mice (24) (25) (26) (27) .
The PTEN gene is frequently deleted or mutated not only in human glioblastoma and prostatic cancer but also in a wide range of advanced human malignancies, such as endometrial, breast, lung, kidney, bladder, testis, and head and neck cancers, malignant melanoma, and lymphoma (17, 18, (28) (29) (30) (31) . The PTEN gene is also mutated in some human genetic diseases, such as Cowden disease (32) and Bannayan-Zonana syndrome (33) . [For a recent review on the genetics of PTEN, see Ali et al. (34) .]
In cancers involving PTEN gene somatic alterations, mutation of the PTEN gene is reported to occur generally late in tumor development. For example, the PTEN gene is frequently mutated in high-grade but not in low-grade gliomas or prostate cancers (17, 18, 29, (35) (36) (37) (38) (39) (40) (41) . A majority (but not all) of these mutations are clustered in the phosphatase homology domain, particularly in the core motif of conserved amino acids. Besides mutation, however, the PTEN gene can also be inactivated in advanced prostate cancer through loss of expression (42) . These findings suggest that inactivation of the PTEN gene plays important roles in tumor progression in some important cancers. In fact, recent genetic and biochemical studies have implicated PTEN in the regulation of several different cellular processes: cell growth, apoptosis (i.e., programmed cell death), interactions with the extracellular matrix, and cell migration and invasion. It is logical that a tyrosine phosphatase such as PTEN could be a tumor suppressor because certain phosphatases can act directly to counter the action of tyrosine kinases (43, 44) .
INTEGRIN SIGNALING
Integrin-mediated adhesion to the extracellular matrix plays important roles in regulating cell survival, proliferation, and motility. It was interesting to determine whether PTEN had effects on integrin signaling because of PTEN's sequence similarity to the cytoskeletal protein tensin (17, 18) , which is intimately involved in integrin-signaling complexes (45) . During the past few years, it has become clear that integrins are involved not only in cell adhesion but also in signal transduction in both normal and tumor cells.
The integrin family is composed of pairs of ␣ and ␤ transmembrane subunits, which are selected from among at least 16 ␣ and eight ␤ subunits to form more than 20 different ␣␤ heterodimeric receptors on cell surfaces; each subunit contributes to ligand selectivity of the integrin (3, (5) (6) (7) 46) . Integrins can directly activate many intracellular signaling events after stimulation by extracellular matrix proteins or by antibodies that bind to specific sites of integrins. Both receptor clustering and ligand occupancy are critical for the activation of intracellular integrinmediated responses (47) . Activation of intracellular signals includes tyrosine phosphorylation of focal adhesion kinase (FAK), which binds to the integrin ␤ 1 cytoplasmic domain and is one of the molecules that co-clusters with ␤ 1 integrins aggregated by noninhibitory anti-integrin antibodies (45, 48, 49) . Integrins and their cytoplasmic tails are involved in forming large complexes of signaling molecules that include Src family kinases (50); cytoskeletal proteins, such as ␣-actinin (51, 52) , talin (53), paxillin (54) , and p130
Cas (55) (56) (57) ; and other signal transduction molecules, such as growth factor receptors (58) (59) (60) , mitogenactivated protein (MAP) kinase (61) (62) (63) , Ras (64) , NF-B (65), phosphatidylinositol 3-kinase (PI 3-K) (66) , protein kinase C (67, 68) , insulin receptor substrate-1 (69), caveolin-1 (70) , and c-Jun amino-terminal kinase (JNK) (45, 71) .
Furthermore, integrins can function in additive or cooperative fashion with growth factors such as platelet-derived growth factor (PDGF) (58, (72) (73) (74) . Previous studies (60, 68) have also implicated serine/threonine kinases in various integrin functions. These additional kinases may provide further layers of control in integrin signaling. Thus, many of the well-known signaling pathways identified previously for growth factors and cytokines are also activated by integrins, thereby making integrinmediated signaling complex. In fact, integrins are remarkably multifunctional. Integrin signaling regulates the following: cell adhesion, spreading, migration, and invasion; cytoskeletal organization; gene expression, such as immediate early genes; apoptosis; cell cycle and growth; Ca 2+ influx; and H + exchange (6, 7, 9, (75) (76) (77) (78) (79) (80) (81) .
ROLES OF INTEGRINS IN GROWTH AND CANCER
The characteristics of malignant cells include uncontrolled cell growth and invasive and metastatic behavior (82, 83) . There are also frequently major differences in cytoskeletal organization between normal and malignant cells. These differences clearly contribute to the motile, invasive, and metastatic phenotype of malignant cells. A critical aspect of invasive and metastatic behavior involves adhesive interactions of tumor cells with other cells or extracellular matrix through the integrin family of cell surface receptors (3) (4) (5) 78, 79, 81, 84, 85) . Integrin-mediated signaling and integrin modulation of mitogenic signals probably play an important role in tumor growth and behavior.
It is well known that transformed cells frequently (but not always) express less cell surface fibronectin than their normal counterparts, with the reduced level of fibronectin contributing to alterations in adhesiveness, motility, and morphology observed in tumor cells (86) (87) (88) . Roles for integrins ␣ 5 ␤ 1 and ␣ v ␤ 3 in cancer seem relatively well validated, although studies of integrin expression in transformed cells [reviewed in (85) ] suggest that various integrin subunits may make either positive or negative contributions to the transformed phenotype. High levels of expression of the ␣ 5 ␤ 1 integrin are negatively associated with transformation and tumor formation (89, 90) , whereas increased expression of ␣ v ␤ 3 is positively associated with increased malignancy in melanomas (91, 92) . Integrins on tumor cells are thought to play intrinsic roles in the progression of some tumors. Overexpression of ␣ 5 ␤ 1 integrin in Chinese hamster ovary cells or colon carcinoma cells results in a loss of tumorigenicity and reduced proliferation (90, 93) . Conversely, loss of ␣ 5 ␤ 1 integrin expression in Chinese hamster ovary cells leads to enhanced tumorigenicity (89) . These findings indicate that ␣ 5 ␤ 1 integrin is implicated in the growth regulation of tumor cells.
Integrin activation of signaling, gene expression, and growth regulation is complex (94) (95) (96) . Integrin-mediated cell adhesion has been found to regulate several cyclins and cyclin-dependent kinases (CDKs) (97) (98) (99) . Several reports have raised the possibility that the integrin-signaling protein FAK may regulate cell proliferation. In BALB/c 3T3 and human endothelial cells, inhibition of FAK by either microinjection of an inhibitory Cterminal fragment or anti-FAK monoclonal antibody induces cell cycle arrest (100) . A recent study (101) showed that overexpression of FAK accelerates the G 1 -to S-phase transition, whereas a dominant-negative FAK mutant inhibits cell cycle progression at G 1 . However, certain integrins are reported to regulate cell proliferation via Shc (Src homology 2-containing protein) (69) . Shc is an SH2-phosphotyrosine-binding adapter protein that links tyrosine kinases to Ras signaling by recruiting the Grb2-Sos complex (70) .
Many mammalian cell types are dependent on adhesion to the extracellular matrix for their continued survival. A variety of normal cell types undergo apoptosis when they lose attachment to an appropriate extracellular matrix in a process termed "anoikis" (102) . In contrast, tumor cells frequently lack this require-ment for anchorage, which is termed "anchorage independence of growth" and is associated closely with tumorigenicity. Multiple integrin-dependent pathways are likely to be involved in protection from apoptotic cell death. Adhesion mediated by integrins not linked to Shc results in cell cycle arrest and apoptosis even in the presence of mitogens (103) , suggesting that Shc may play an important role in integrin-mediated cell survival. In addition, JNK is also activated early after detachment from matrix and has been suggested to be responsible for inducing apoptosis (71) .
Some studies have also pointed to key roles for FAK in this cell survival signal from the extracellular matrix. Levels of FAK expression are often increased in proliferating cells or advanced invasive cancers (104) (105) (106) . Expression of membrane-anchored FAK, which is constitutively activated in suspended cells, prevents cell detachment-induced apoptosis (anoikis) of MDCK (Madin-Darby canine kidney) cells (71) . Conversely, inhibition of FAK by microinjection of either the dominant-negative FAK truncation termed "FRNK" (FAK-related non-kinase) or an anti-FAK antibody causes cell cycle arrest and apoptosis (100, 107) . FAK seems to be an important mediator of integrin-mediated survival signals upstream of the PI 3-K/Akt pathway. (Akt is also termed "protein kinase B" or "PKB.") Akt is a survivalpromoting serine-threonine protein kinase regulated by PIP 3 that is implicated in survival signaling in a wide variety of cells, including fibroblastic, epithelial, and neuronal cells (108) .
Attachment of cells to the matrix leads to the association of the p85 subunit of PI 3-K with tyrosine residue 397 in FAK (66) and rapid elevation of the levels of PI 3-K lipid products and Akt activity and protection from apoptosis (109) . PI 3-K is required for integrin-stimulated Akt activation (110) . Furthermore, constitutively active forms of FAK or PI 3-K can protect cells from suspension-induced apoptosis (102, 109) . FAK is also reported to suppress a p53-dependent pathway activated by protein kinase C / and cytosolic phospholipase A2, and it inhibits apoptosis under serum-starved conditions (111) . These results provide evidence that FAK may be a major mediator of integrin-dependent cell survival.
PTEN AND FAK IN INTEGRIN SIGNALING
A large variety of intracellular regulatory enzyme pathways can control the formation of focal adhesions and actin cytoskeleton organization. Integrin clustering under restrictive conditions induces co-localization of FAK and tensin without other cytoskeletal or signaling proteins (47) , suggesting that FAK might play a central role in the signal transduction pathway triggered by integrins. FAK co-localizes with integrins at focal adhesions, and its protein kinase activity is enhanced by cell binding to extracellular matrix proteins (48) . Peptides derived from the juxtamembrane region of the ␤ integrin cytoplasmic domain can bind to the N-terminal domain of FAK in vitro (112) . FAK may also interact with integrins through interactions with proteins, such as paxillin and talin, that involve the focal adhesion targeting region in the FAK C-terminal domain, which might contribute to cytoskeletal formation and signal transduction by recruiting cytoskeletal and signaling molecules (6) . FAK contains a central kinase domain flanked by large N-and Cterminal domains that contain regions of sequence similarity surrounding phosphorylation sites and proline-rich regions that are binding sites for SH3-domain-containing proteins, such as p130 Cas . There are at least six sites of in vivo tyrosine phosphorylation. Integrin-dependent oligomerization of FAK enhances transphosphorylation at tyrosine 397, and this autophosphorylation in turn recruits Src-family protein kinases, resulting in the phosphorylation of other tyrosine residues in FAK including tyrosine 576 and 577 in the FAK activation loop, thereby promoting full catalytic activation (113) (114) (115) (116) . Tyrosine 397 is also a binding site for the SH2 domains of the regulatory subunit (p85) of PI 3-K, and FAK association with PI 3-K triggers activation of PI 3-K and its signaling pathways (66, 117) . Tyrosine 925 can also be a binding site for Grb2 (62) . Grb2 recruitment to FAK of the Sos guanosine diphosphate/guanosine triphosphate exchange factor for Ras is a direct link to the activation of the extracellular signal-regulated kinase (ERK)/ MAP kinase pathway. Besides Grb2, FAK phosphorylation of paxillin and p130 Cas could also lead to activation of the MAP kinase pathway through adapter proteins, such as Crk and Nck (57, 118) . However, FAK may not be the only signaling protein involved in integrin-mediated MAP kinase activation (70, 103, 118, 119) . Lin et al. (119) have reported that integrinmediated activation of MAP kinase can be independent of FAK in fibroblasts. Furthermore, caveolin-1 was recently shown to link certain integrin ␣ subunits to Shc through the tyrosine kinase Fyn, which leads to Ras/ERK pathway activation (70) .
FAK is tyrosine phosphorylated upon integrin activation, and focal adhesion-associated phosphatases could modulate FAKassociated signaling complexes and FAK functions. A couple of phosphatases have been suggested as candidates for modulating molecules in integrin complexes: Protein tyrosine phosphatase ␣ and PTP-PEST (a protein tyrosine phosphatase [PTP] with a carboxy-terminal segment rich in proline, glutamic acid, aspartic acid, serine, and threonine [PEST] residues) negatively regulate Src and paxillin, respectively (120, 121) . Protein tyrosine phosphatase 1B directly binds to p130
Cas and N-cadherin and regulates integrin-and cadherin-mediated adhesion (122) (123) (124) .
Recently, however, it has been shown that PTEN interacts directly with and dephosphorylates FAK tyrosine phosphate and that it inhibits integrin-mediated cell spreading, migration, invasion, and cytoskeletal organization (125, 126) . The phosphatase domain of PTEN is essential for all of these functions because protein tyrosine phosphatase-inactive mutants of PTEN have no effect. It has been proposed that FAK plays roles in many biologic functions. Studies have further implicated FAK in integrinmediated regulation of cell spreading and migration. FAK expression is enhanced in rapidly migrating keratinocytes (127) and in invasive human tumors (104) , and migration of endothelial cells is also positively associated with FAK phosphorylation and kinase activity (128) . Cells from FAK-deficient mice (129) and cells in which FAK signaling is inhibited by microinjection of FRNK (100) exhibit reduced cell migration, whereas overexpression of FAK increases migration toward fibronectin in Chinese hamster ovary cells (130) . Overexpression of FRNK inhibits phosphorylation of endogenous FAK and cell spreading and migration (100, 131) , which is consistent with the observation that PTEN-induced FAK dephosphorylation leads to suppression of cell spreading and migration (125) . FAK/PI 3-K association could activate PI 3-K, which is also implicated in stimulating cell migration in PDGF-induced chemotaxis (132) .
The signal transduction protein p130 Cas seems to be a major mediator of FAK-promoted cell migration. p130
Cas binds directly to FAK and is phosphorylated upon cell adhesion to extracellular matrix proteins in an FAK-and Src-dependent man-ner (55, 57, 133, 134) . The proline-rich region of FAK spanning amino acids 711-717 has been demonstrated to be a binding site for the SH3 domain of p130
Cas (135) . Formation of the FAK/ p130
Cas complex leads to coupling to the adapter protein c-CrkII and targets downstream pathways in mediating FAK-promoted cell migration (136, 137) .
FAK is also implicated in cell invasion. Although FAK expression levels are normal in benign adenomatous tissues, its expression is increased in invasive and metastatic tumors (106) . FAK is required for fibronectin-mediated invasion in ovarian cancer cells (138) . Hepatocyte growth factor/scatter factorinduced activation of FAK promotes migration and invasion by oral squamous cell carcinoma cells (139) . Consistent with the role for FAK/p130
Cas in cell migration and invasion, PTEN gene restoration in cells with mutated alleles causes a decrease in p130
Cas phosphorylation, accompanied by inhibition of cell migration and invasion; overexpression of either FAK or p130 Cas can restore their phosphorylation and rescue cell migration and invasion (126) . Thus, the elevated FAK observed in transformed cells may form complexes with p130
Cas , leading to invasion events involved in the dissemination of tumors. PTEN gene inactivation in cancers may contribute to this event by loss of inhibition of this FAK/p130
Cas pathway regulating migration and invasion. An important area for future research will be to determine the mechanisms by which PTEN gene mutations may contribute to tumor progression. When a tumor loses its PTEN gene, a low-grade tumor is likely to become more malignant, but direct information on causality and mechanisms is still lacking.
PTEN AND CELL GROWTH
PTEN expression in PTEN gene-mutated glioma cells suppresses cell growth (140) and induces apoptosis (25) . PTEN inhibits tumorigenicity in glioma cells missing the PTEN gene and in embryonic stem cells (24, 141) . PTEN gene null (−/−) mouse embryos exhibit extensive proliferation but undergo early embryonic lethality (24, 25, 27) . The role for the PTEN gene in embryonic development is still uncertain (142); Di Cristofano et al. (24) reported that the PTEN gene is required for the differentiation of endoderm, mesoderm, and ectoderm, whereas Suzuki et al. (26) reported that the PTEN gene is required for patterning of the cephalic and caudal regions of the embryo and for placental development. However, these results suggest that the PTEN gene may act in normal tissues to guide the development of cellular interactions such that cells, tissues, and organs are properly formed with respect to one another. Furthermore, PTEN gene heterozygous mice develop hyperplastic changes in the prostate, skin, and colon (24) and in the endometrium, liver, prostate, gastrointestinal tract, thyroid, and thymus (27) or T-cell lymphoma, teratocarcinoma, and prostatic cancer (26) . Molecular examination of these tumors revealed that the wild-type PTEN allele had been lost in many cases, confirming the role of the PTEN gene as a tumor suppressor (26, 27) . It remains unknown whether PTEN gene mutation is the only cause of development of hamartomas and cancer in patients with Cowden disease and in PTEN gene heterozygous mice. It should also be noted that the patterns of tumor formation, as well as the effects on embryonic development, differ in the different mouse PTEN gene knockout models described to date, suggesting that genetic background can substantially modify the effects of PTEN gene deletion.
PTEN can selectively inhibit both integrin-and growth factor-mediated activation of the ERK type of MAP kinase pathway (143) , although PTEN has no effect on basal MAP kinase activities without any stimulation (141) . The specific point of MAP kinase inhibition by PTEN seems to be at the level of Shc phosphorylation because Shc phosphorylation and Ras activity are inhibited by expression of PTEN, whereas EGF receptor autophosphorylation is unaffected. Furthermore, PTEN can directly interact with and dephosphorylate Shc tyrosine phosphate (144) . PTEN negatively regulates two distinct additive pathways regulating cell motility: One involves Shc, an MAP kinase pathway, and random migration, whereas the other involves FAK, p130 Cas , more extensive actin cytoskeletal organization, focal contacts, and directionally persistent cell motility (144) . EGF receptor signaling does not appear to require PI 3-K activation (110) , making it unlikely that the effects of PTEN on MAP kinase activation by this pathway occurs by effects on phosphoinositides. Activation of MAP kinase has been shown to stimulate cell migration by phosphorylating myosin light chain kinase (145) . PTEN inhibition of cell spreading and focal contact formation are partially rescued by coexpression of constitutively activated MEK1 (MAP kinase/ERK kinase 1), suggesting the involvement of the Shc/MAP kinase pathway in PTEN-mediated signaling (143, 144) . It remains to be clarified whether this MAP kinase pathway is also involved in PTEN regulation of cell growth.
Recently, PIP 3 , which is produced by PI 3-K and can activate protein kinase B (Akt) (146) , has also been identified as a substrate of PTEN besides FAK (22) . PTEN directly dephosphorylates the D3 position of PIP 3 (22) , which appears to be an important mechanism in PTEN suppression of cell growth or apoptosis. The Caenorhabditis elegans PTEN gene homologue DAF-18 also has 3-phosphatase activity toward PIP 3 (147) , supporting the importance of this substrate. Although overexpression of FAK can antagonize the biologic effects of PTEN on cell migration and invasion, overexpression of FAK rescues only partially the action of PTEN on growth suppression, and p130 Cas does not affect growth (126) , indicating that the cell growthsuppressive effect of PTEN is not mediated by FAK alone and that downstream effectors other than p130
Cas , such as PIP 3 , play a more critical role in cell growth.
Activation of Akt has been implicated in protection of cells from apoptosis in response to several signals, including growth factors (108, 148) , cytokines (149), c-Myc overexpression (150) , UV irradiation (108), CD95/Fas-induced cell death (151) , and matrix detachment (109, 152) . Activation of Akt leads to phosphorylation of the Bcl-2 family member Bad, thereby suppressing apoptosis and promoting cell survival (153) . In PTEN genemutated glioblastoma cells and mouse embryonic fibroblasts, the activity of Akt is constitutively elevated, although activation of Akt by insulin or PDGF is unaffected (25, 143, 154) . PTEN expression in PTEN gene-mutated glioma cells increases sensitivity to cell death in response to several apoptotic stimuli, including UV irradiation and treatment with tumor necrosis factor-␣ (25) .
PTEN has also been implicated in regulating the anoikis apoptotic response to loss of integrin-mediated adhesion by detachment from extracellular matrix. In one study (155) , restoration of PTEN to glioma cells increased the rate of apoptosis after detachment by approximately twofold. Another study (156) , however, found that PTEN expression in a number of breast carcinoma cell lines induced apoptosis even in the presence of cell attachment. A third study (157) has recently found that glioma cells display a striking restoration of sensitivity to anoikis after PTEN reconstitution. PTEN-dependent cell death can be rescued by coexpression of downstream Akt (156) . PTEN also impairs activities of the translation repressor 4E-BP1 and the c-fos gene promoter, which are downstream targets of the PI 3-K/Akt pathway (156, 158) .
In some cells, PTEN-dependent apoptosis could not be rescued by expression of upstream PI 3-K, consistent with PTENnegative regulation of the PI 3-kinase/Akt pathway at the level of PIP 3 (156) . Overexpression of FAK in PTEN genetransfected glioma cells to levels that restored phosphorylated FAK levels, as well as PI 3-K binding to FAK and PI 3-K enzymatic activity, resulted in only partial restoration of PIP 3 levels and only partial rescue from anoikis. The latter studies suggest that PTEN can act at two steps-at an upstream site involving FAK that can regulate PI 3-K activity and directly on PIP 3 itself as a substrate. Both steps may contribute to a crucial role for the PTEN gene in anoikis (157) . In fact, a defect in the regulation of apoptosis is seen in vivo in lymphoid tissues of PTEN −/− mice in which a decrease in annexin V staining was observed (27) .
The effects of PTEN on the cell cycle appear to depend on the experimental system. Experimental PTEN overexpression in the human glioma U87MG cell line, in which the endogenous PTEN gene is mutated, induces G 1 arrest only when cells are cultured under serum-restricted (2% serum) culture conditions, and there is no suppression in 10% serum (159) . However, other studies (141, 160, 161) have reported G 1 arrest under 10% serum conditions involving Akt, CDK2, and Rb (retinoblastoma) downstream of PTEN in cell cycle control. Other studies reported no differences in cell cycle distribution between PTEN gene knockout and wild-type embryonic stem cells (24) or an accelerated G 1 /S transition with suppression of p27 KIP1 activity (162) . These divergent in vitro studies suggest that there are cell type and PTEN dosage-dependent differences in the cell cycle effects of PTEN. Examination of in vivo sites of hyperplasia seen in the prostate of PTEN −/− mice revealed increases in mitotic index and Ki-67 staining (24) .
Suppression of growth, invasion, and migration in glioma cells with mutated PTEN alleles by expression of exogenous PTEN requires a functional phosphatase catalytic domain (126, 140) . Certain missense mutations of PTEN flanking the catalytic domain, such as PTEN-G129E (glycine to glutamic acid at position 129), can specifically ablate the ability of PTEN to recognize phospholipids as a substrate but still retain protein phosphatase activity (154) . These mutants demonstrate that the lipid phosphatase activity of PTEN is necessary for cell growth function (154) and cell cycle arrest (159) . In contrast, studies of this same G129E mutation found in some tumors (125, 126) indicate that protein phosphatase activity (without lipid phosphatase effects) can suppress FAK-mediated cell spreading, migration, invasion, and cytoskeletal formation. Taken together, these findings suggest that these latter cellular functions alone are not sufficient to suppress tumorigenesis (or Cowden disease). They may instead contribute to tumor progression, especially since current data suggest that many somatic mutations in the PTEN gene appear later in tumor development.
A second type of mutation that may be valuable to study suggests that there may be potential function(s) in the C-terminal domain of PTEN: Many nonsense mutations described in human tumors cluster around amino acid 233 of PTEN C-terminus outside the tensin homology and phosphatase domains. These mutations would create a truncated PTEN molecule with intact tensin and phosphatase homology domains. In addition, this residue is located at potential tyrosine phosphate acceptor sites (residues 233-240 and 308-315) (18) , suggesting a possible role for C-terminal site(s) in post-translational regulation; functions of this region clearly need further exploration.
On the basis of current knowledge in the field, we propose that PTEN has dual functions as a tumor suppressor: (a) It helps to regulate apoptosis and growth through its lipid phosphatase activity, which regulates levels of PIP 3 , activation of Akt/PKB, and the processes of apoptosis and anoikis; but (b) it also contributes to the regulation of cell adhesion, migration, tumor cell invasion, cytoskeletal organization, and MAP kinase activation through its protein tyrosine phosphatase activity targeting FAK and Shc (Fig. 1) . The latter effects may be particularly relevant to later cancer progression, specifically to steps involved in cancer invasion and metastasis. We also suggest that various types of cross-talk between components of these pathways may exist; e.g., PTEN dephosphorylation of FAK appears to enhance its effects on PIP 3 . In addition, there are likely to be cell type Fig. 1 . Model of the PTEN signaling network. Extracellular matrix (ECM) binding to integrin receptors triggers intracellular signaling associated with local accumulation of a number of cytoskeletal and signal transduction molecules, including focal adhesion kinase (FAK) and Shc, a phosphotyrosine-binding adapter protein. These and many other proteins form signaling and cytoskeletal protein complexes, which anchor the F-actin (i.e., filamentous actin)-containing cytoskeleton. Receptors for growth factors can also transiently associate with these multimolecular complexes, which are involved in focal adhesion formation, cell migration, invasion, and potentially in cell growth modulation. PTEN dephosphorylates FAK tyrosine phosphate directly and negatively regulates cell migration, invasion, and-partially-growth. PTEN also dephosphorylates Shc (Src homology 2-containing protein) tyrosine phosphate directly and negatively regulates an MAP (mitogen-activated protein) kinase signaling cascade starting with Grb2 and Sos and ending in ERK (extracellular signal-regulated kinase). Both the FAK-p130
Cas (Cas) pathway and the Shc-ERK/MAP kinase pathway are involved in PTEN suppression of cell adhesion, migration, and invasion; however, p130
Cas is not involved in PTEN effects on cell growth. In addition, PTEN is known to dephosphorylate directly the signaling lipid PIP 3 (phosphatidylinositol 3,4,5-trisphosphate) and negatively regulates a downstream Akt/ PKB (protein kinase B) cell survival pathway directly or via a process involving FAK and PI 3-K (phosphatidylinositol 3-kinase). Thus, PTEN regulation of different signaling pathways of FAK, Shc, and PIP 3 implicates it in an increasingly complex network of signal transduction processes. differences in the roles of the PTEN protein in these different processes.
PTEN is the first tumor suppressor gene that has phosphatase activity. However, it is not surprising that the loss of a phosphatase should contribute to oncogenesis because it functions as a regulatory molecule that acts in opposition to kinases. Mutations of the PTEN gene are observed in a wide variety of cancers, suggesting that the PTEN gene plays a critical role in oncogenesis in many tissues. Recent studies have elucidated PTEN's tumor-suppressive function, affecting growth apoptosis, invasion, and the cytoskeleton. PTEN consequently has complex but important effects on signaling and cell biologic processes. Elucidation of these novel regulatory pathways may lead to fresh, new approaches to cancer therapy
